Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pickering

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Nature Communications|January 3, 2024
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA responseMei Zhao, Tianxiao Wang, Frederico O Gleber-Netto, et al.
Advances in Radiation Oncology|November 24, 2022
Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234Chieko Michikawa, Pedro A Torres-Saavedra, Natalie L Silver, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2015
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, et al.
Neoplasia (New York, N.Y.)|July 14, 2022
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)Chieko Michikawa, Vancheswaran Gopalakrishnan, Amani M Harrandah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Journal of the National Cancer Institute|September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
Journal for Immunotherapy of Cancer|April 22, 2021
Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axisMichael W Knitz, Thomas E Bickett, Laurel B Darragh, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2018
Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2Byung-Kwon Choi, Tajhal Dayaram, Neha Parikh, et al.
Nature|February 14, 2020
Loss of p53 drives neuron reprogramming in head and neck cancerMoran Amit, Hideaki Takahashi, Mihnea Paul Dragomir, et al.
Cancer Research|February 19, 2015
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsAbdullah A Osman, David M Neskey, Panagiotis Katsonis, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Nature Communications|January 3, 2024
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA responseMei Zhao, Tianxiao Wang, Frederico O Gleber-Netto, et al.
Advances in Radiation Oncology|November 24, 2022
Evolutionary Action Score of <i>TP53</i> Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234Chieko Michikawa, Pedro A Torres-Saavedra, Natalie L Silver, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2015
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, et al.
Neoplasia (New York, N.Y.)|July 14, 2022
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)Chieko Michikawa, Vancheswaran Gopalakrishnan, Amani M Harrandah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Journal of the National Cancer Institute|September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
Journal for Immunotherapy of Cancer|April 22, 2021
Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axisMichael W Knitz, Thomas E Bickett, Laurel B Darragh, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2018
Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2Byung-Kwon Choi, Tajhal Dayaram, Neha Parikh, et al.
Nature|February 14, 2020
Loss of p53 drives neuron reprogramming in head and neck cancerMoran Amit, Hideaki Takahashi, Mihnea Paul Dragomir, et al.
Cancer Research|February 19, 2015
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsAbdullah A Osman, David M Neskey, Panagiotis Katsonis, et al.
Pageof 17